Table 1.
Participants and response to BNT162b2 mRNA vaccine
| Variable | Dialysis patients (n = 160) | Control group (n = 132) | P value |
|---|---|---|---|
| Age, median [IQR], yr | 69 [62–78] | 50.5 [41–60] | <0.001 |
| Male | 101 (63) | 67 (51) | 0.022 |
| Female | 59 (37) | 65 (49) | |
| Hemodialysis | 127 (79) | — | — |
| Peritoneal dialysis | 33 (21) | — | — |
| Dialysis vintage, median [IQR], yr | 3.21 [1.60–5.39] | — | — |
| Anti–spike antibody negative (<15 AU/ml) | 16 (10) | 0 | <0.001 |
| Anti–spike antibody level, median [IQR], AU/ml | 116.5 [66.0–160.0] | 176.5 [142–235] | <0.001 |
| COVID-19 infection after complete vaccination | 6 (3.75) | 0 | 0.033 |
AU, arbitrary unit; COVID-19, coronavirus disease 2019; IQR, interquartile range.
Data are given as n (%), unless otherwise indicated.